John H Griffin

List of Publications by Year
in descending order

384 papers	20,557 citations	9264 74 h-index	14208 128 g-index
388 all docs	388 docs citations	388 times ranked	11936 citing authors

#	Article	IF	Citations
1	Deficiency of protein C in congenital thrombotic disease.. Journal of Clinical Investigation, 1981, 68, 1370-1373.	8.2	1,130
2	The cytoprotective protein C pathway. Blood, 2007, 109, 3161-3172.	1.4	714
3	Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10068-10073.	7.1	634
4	Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nature Medicine, 2003, 9, 338-342.	30.7	556
5	Endothelial and Antithrombotic Actions of HDL. Circulation Research, 2006, 98, 1352-1364.	4.5	552
6	Endotoxemia and sepsis mortality reduction by non-anticoagulantâ€“activated protein C. Journal of Experimental Medicine, 2007, 204, 2439-2448.	8.5	319
7	Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.. Proceedings of the National Academy of Sciences of the United States of America, 1976, 73, 2554-2558.	7.1	267
8	Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Critical Care Medicine, 2000, 28, 2209-2216.	0.9	248
9	A Single Genetic Origin for a Common Caucasian Risk Factor for Venous Thrombosis. Blood, 1997, 89, 397-402.	1.4	246
10	Activated Protein C Prevents Neuronal Apoptosis via Protease Activated Receptors 1 and 3. Neuron, 2004, 41, 563-572.	8.1	243
11	Activated protein C inhibits tissue plasminogen activatorâ€“induced brain hemorrhage. Nature Medicine, 2006, 12, 1278-1285.	30.7	243
12	Role of surface in surface-dependent activation of Hageman factor (blood coagulation Factor XII). Proceedings of the National Academy of Sciences of the United States of America, 1978, 75, 1998-2002.	7.1	225
13	Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochemical Journal, 2003, 373, 65-70.	3.7	219
14	Activated protein C: biased for translation. Blood, 2015, 125, 2898-2907.	1.4	212
15	Anti-Inflammatory, Antithrombotic, and Neuroprotective Effects of Activated Protein C in a Murine Model of Focal Ischemic Stroke. Circulation, 2001, 103, 1799-1805.	1.6	202
16	Activated protein C. Journal of Thrombosis and Haemostasis, 2007, 5, 73-80.	3.8	202
17	Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7830-7835.	7.1	198
18	High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. Journal of Clinical Investigation, 1999, 103, 219-227.	8.2	197

#	Article	IF	Citations
19	Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood, 2012, 120, 5237-5246.	1.4	191
20	Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease.. Journal of Clinical Investigation, 1980, 66, 1186-1189.	8.2	191
21	Bloodâ€“spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1035-42.	7.1	188
22	Role of high-molecular-weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein.. Proceedings of the National Academy of Sciences of the United States of America, 1977, 74, 4636-4640.	7.1	174
23	Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood, 2004, 104, 1740-1744.	1.4	167
24	American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. Genetics in Medicine, 2001, 3, 139-148.	2.4	166
25	Synthesis and Properties of Metalloporphyrin Monolayers and Stacked Multilayers Bound to an Electrode via Site Specific Axial Ligation to a Self-Assembled Monolayer. Journal of the American Chemical Society, 1998, 120, 4478-4487.	13.7	160
26	Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. Journal of Clinical Investigation, 2009, 119, 3437-49.	8.2	158
27	High-Density Lipoprotein Deficiency and Dyslipoproteinemia Associated With Venous Thrombosis in Men. Circulation, 2005, 112, 893-899.	1.6	156
28	Protein S binds to and inhibits factor Xa.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2728-2732.	7.1	153
29	The Binding and Cleavage Characteristics of Human Hageman Factor during Contact Activation. Journal of Clinical Investigation, 1977, 59, 1167-1175.	8.2	150
30	Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.. Journal of Experimental Medicine, 1978, 147, 719-729.	8.5	150
31	Activation of Human Factor VII in Plasma and in Purified Systems. Journal of Clinical Investigation, 1979, 64, 1056-1065.	8.2	148
32	Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci. Journal of the American Chemical Society, 1996, 118, 13107-13108.	13.7	139
33	The Biochemistry and Pathophysiology of the Contact System of Plasma. Advances in Immunology, 1982, 33, 241-306.	2.2	132
34	Variability of Thrombosis among Homozygous Siblings with Resistance to Activated Protein C Due to an Arg-to-Gln Mutation in the Gene for Factor V. New England Journal of Medicine, 1994, 331, 1559-1562.	27.0	131
35	Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.. Circulation, 1990, 82, 578-585.	1.6	130
36	Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 274-279.	7.1	130

#	Article	IF	Citations
37	Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends in Neurosciences, 2011, 34, 198-209.	8.6	129
38	Tissue Plasminogen Activator (tPA) Deficiency Exacerbates Cerebrovascular Fibrin Deposition and Brain Injury in a Murine Stroke Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2801-2806.	2.4	127
39	Cytoprotective activated protein C averts Nlrp3 inflammasomeâ€“induced ischemia-reperfusion injury via mTORC1 inhibition. Blood, 2017, 130, 2664-2677.	1.4	125
40	Recent Advances in The Understanding of Contact Activation Reactions. Seminars in Thrombosis and Hemostasis, 1979, 5, 254-273.	2.7	121
41	Activated Protein C Preserves Functional Islet Mass After Intraportal Transplantation: A Novel Link Between Endothelial Cell Activation, Thrombosis, Inflammation, and Islet Cell Death. Diabetes, 2004, 53, 2804-2814.	0.6	121
42	Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells. Journal of Biological Chemistry, 2006, 281, 20077-20084.	3.4	120
43	The thrombin paradox. Nature, 1995, 378, 337-338.	27.8	117
44	Receptors for high molecular weight kininogen on stimulated washed human platelets. Biochemistry, 1984, 23, 6863-6869.	2.5	114
45	Final Results of the RHAPSODY Trial: A Multiâ€Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3Aâ€APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Annals of Neurology, 2019, 85, 125-136.	5.3	113
46	Protein C anticoagulant and cytoprotective pathways. International Journal of Hematology, 2012, 95, 333-345.	1.6	110
47	[7] Human factor XII (Hageman factor). Methods in Enzymology, 1976, 45, 56-65.	1.0	109
48	Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood, 2009, 113, 2859-2866.	1.4	108
49	Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate. Biochemistry, 1980, 19, 1151-1160.	2.5	107
50	Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood, 2003, 101, 4797-4801.	1.4	107
51	Activated Protein C Mutant with Minimal Anticoagulant Activity, Normal Cytoprotective Activity, and Preservation of Thrombin Activable Fibrinolysis Inhibitor-dependent Cytoprotective Functions. Journal of Biological Chemistry, 2007, 282, 33022-33033.	3.4	106
52	Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood, 2012, 119, 874-883.	1.4	106
53	Impairments of the Protein C System and Fibrinolysis in Infection-Associated Stroke. Stroke, 1996, 27, 2005-2011.	2.0	106
54	Binding of coagulation factor XI to washed human platelets. Biochemistry, 1986, 25, 3884-3890.	2.5	105

#	Article	IF	Citations
55	Activated Protein C Promotes Neovascularization and Neurogenesis in Postischemic Brain via Protease-Activated Receptor 1. Journal of Neuroscience, 2008, 28, 12788-12797.	3.6	104
56	High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism. Circulation, 2007, 115, 1609-1614.	1.6	102
57	Pharmacological targeting of the thrombomodulinâ€“activated protein C pathway mitigates radiation toxicity. Nature Medicine, 2012, 18, 1123-1129.	30.7	97
58	Purification and characterization of plasma protein C inhibitor. Thrombosis Research, 1989, 55, 369-384.	1.7	95
59	Steric and Electronic Effects, Enantiospecificity, and Reactive Orientation in DNA Binding/Cleaving by Substituted Derivatives of [SalenMnIII]+. Inorganic Chemistry, 1996, 35, 4837-4847.	4.0	95
60	Plasma Lipoproteins, Hemostasis and Thrombosis. Thrombosis and Haemostasis, 2001, 86, 386-394.	3.4	95
61	Cardiolipin is a normal component of human plasma lipoproteins. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1743-1748.	7.1	94
62	Activated protein C, protease activated receptor 1, and neuroprotection. Blood, 2018, 132, 159-169.	1.4	94
63	A comparision of the abilities of plasma kallikrein, Î²-factor XIIa, factor XIa and urokinase to activate plasminogen. Thrombosis Research, 1983, 29, 407-417.	1.7	90
64	3K3Aâ€“activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice. Nature Medicine, 2016, 22, 1050-1055.	30.7	88
65	Specific DNA cleavage mediated by manganese complex [SalenMn(III)]+. Journal of Organic Chemistry, 1993, 58, 820-822.	3.2	86
66	Protein S Confers Neuronal Protection During Ischemic/Hypoxic Injury in Mice. Circulation, 2003, 107, 1791-1796.	1.6	86
67	Activated protein C: Potential therapy for severe sepsis, thrombosis, and stroke. Seminars in Hematology, 2002, 39, 197-205.	3.4	85
68	Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. Journal of Biological Chemistry, 2017, 292, 8616-8629.	3.4	84
69	Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. Journal of Clinical Investigation, 2010, 120, 3167-3178.	8.2	84
70	Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. European Journal of Neuroscience, 2009, 29, 1119-1130.	2.6	83
71	Nucleotide and deduced amino acid sequences of the oxidosqualene cyclase from Candida albicans. Journal of the American Chemical Society, 1992, 114, 9711-9713.	13.7	82
72	Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage. Journal of Biological Chemistry, 2000, 275, 12410-12415.	3.4	81

#	Article	IF	Citations
73	PAR1 biased signaling is required for activated protein C in vivo benefits in sepsis and stroke. Blood, 2018, 131, 1163-1171.	1.4	81
74	Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thrombosis Research, 1990, 59, 593-608.	1.7	78
75	Total chemical synthesis of enzymatically active human type II secretory phospholipase A2. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7845-7850.	7.1	78
76	Molecular assembly in the contact phase of the Hageman factor system. American Journal of Medicine, 1979, 67, 657-664.	1.5	76
77	HUMAN PROTEIN C: INACTIVATION OF FACTORS V AND VIII IN PLASMA BY THE ACTIVATED MOLECULE*. Annals of the New York Academy of Sciences, 1981, 370, 303-310.	3.8	73
78	Activated Protein C Resistance: Molecular Mechanisms. Thrombosis and Haemostasis, 1995, 74, 444-448.	3.4	73
79	Potent Anti- Trypanosoma cruzi Activities of Oxidosqualene Cyclase Inhibitors. Antimicrobial Agents and Chemotherapy, 2001, 45, 1210-1215.	3.2	72
80	Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C. Journal of Biological Chemistry, 2002, 277, 28836-28840.	3.4	72
81	Multivalent Drug Design. Synthesis and In Vitro Analysis of an Array of Vancomycin Dimers. Journal of the American Chemical Society, 2003, 125, 6517-6531.	13.7	72
82	Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood, 2003, 102, 146-151.	1.4	72
83	Activation of Rabbit Hageman Factor by Homogenates of Cultured Rabbit Endothelial Cells. Journal of Clinical Investigation, 1980, 65, 197-206.	8.2	71
84	A structural model for the prostate disease marker, human prostateâ€specific antigen. Protein Science, 1994, 3, 2033-2044.	7.6	71
85	Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells, Molecules, and Diseases, 2003, 30, 271-276.	1.4	71
86	Clinical Studies of Protein C. Seminars in Thrombosis and Hemostasis, 1984, 10, 162-166.	2.7	69
87	Aprotinin (Trasylol) is a competitive inhibitor of activated protein C. Thrombosis Research, 1989, 56, 751-756.	1.7	69
88	Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thrombosis and Haemostasis, 2009, 101, 724-733.	3.4	69
89	Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood, 2009, 113, 5970-5978.	1.4	68
90	Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates.. Circulation, 1991, 84, 2454-2462.	1.6	67

#	Article	IF	Citations
91	The effect of phospholipids, calcium ions and protein S on rate constants of human factor Va inactivation by activated human protein C. FEBS Journal, 1992, 208, 171-178.	0.2	67
92	Functional recovery after embolic stroke in rodents by activated protein C. Annals of Neurology, 2005, 58, 474-477.	5.3	67
93	Generation and phenotypic analysis of protein Sâ€“deficient mice. Blood, 2009, 114, 2307-2314.	1.4	67
94	Three-dimensional Model of Coagulation Factor Va Bound to Activated Protein C. Thrombosis and Haemostasis, 2000, 84, 849-857.	3.4	66
95	Elucidating the structural chemistry of glycosaminoglycan recognition by protein C inhibitor.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8506-8510.	7.1	65
96	An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents. Stroke, 2012, 43, 2444-2449.	2.0	65
97	EPCR-dependent PAR2 activation by the blood coagulation initiation complex regulates LPS-triggered interferon responses in mice. Blood, 2015, 125, 2845-2854.	1.4	65
98	Central venous thrombosis after cardiac operations in children. Journal of Thoracic and Cardiovascular Surgery, 1996, 112, 883-889.	0.8	64
99	Activated Protein C Resistance in Ischemic Stroke Not Due to Factor V Arginine ⁵⁰⁶ â†'Glutamine Mutation. Stroke, 1996, 27, 1163-1166.	2.0	63
100	Arteriovenous Blood Metabolomics: A Readout of Intra-Tissue Metabostasis. Scientific Reports, 2015, 5, 12757.	3.3	62
101	Immunoblotting studies of the molecular forms of protein C in plasma. Thrombosis Research, 1988, 52, 33-43.	1.7	61
102	Phase 1 Safety, Tolerability and Pharmacokinetics of 3K3A-APC in Healthy Adult Volunteers. Current Pharmaceutical Design, 2014, 19, 7479-7485.	1.9	61
103	Thrombosis in otherwise well children with the factor V Leiden mutation. Journal of Pediatrics, 1996, 128, 324-328.	1.8	60
104	Low Protein Z Levels and Risk of Ischemic Stroke: Differences by Diabetic Status and Gender. Blood Cells, Molecules, and Diseases, 2002, 29, 139-144.	1.4	58
105	Acylideneoxoindoles: A new class of reversible inhibitors of human transglutaminase 2. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2692-2696.	2.2	58
106	Protein S Protects Neurons from Excitotoxic Injury by Activating the TAM Receptor Tyro3â€“Phosphatidylinositol 3-Kinaseâ€“Akt Pathway through Its Sex Hormone-Binding Globulin-Like Region. Journal of Neuroscience, 2010, 30, 15521-15534.	3.6	57
107	Targeting anticoagulant protein S to improve hemostasis in hemophilia. Blood, 2018, 131, 1360-1371.	1.4	57
108	Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats. Stroke, 2013, 44, 3529-3536.	2.0	56

#	Article	IF	Citations
109	Potent Blood Coagulant Activity of Human Semen Due to Prostasome-Bound Tissue Factor1. Biology of Reproduction, 1997, 56, 757-763.	2.7	55
110	Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood, 2001, 97, 1907-1914.	1.4	55
111	3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. Journal of Experimental Medicine, 2019, 216, 279-293.	8.5	55
112	Binding sites for blood coagulation factor Xa and protein S involving residues 493â€“506 in factor Va. Protein Science, 1996, 5, 1883-1889.	7.6	54
113	Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Frontiers in Bioscience - Landmark, 2006, 11, 2381.	3.0	54
114	An Activated Protein C Analog Stimulates Neuronal Production by Human Neural Progenitor Cells via a PAR1-PAR3-S1PR₁-Akt Pathway. Journal of Neuroscience, 2013, 33, 6181-6190.	3.6	54
115	Determination of functional and antigenic protein C inhibitor and its complexes with activated protein C in plasma by ELISA's. Thrombosis Research, 1989, 55, 671-682.	1.7	52
116	Homology Models of the C Domains of Blood Coagulation Factors V and VIII: A Proposed Membrane Binding Mode for FV and FVIII C2 Domains. Blood Cells, Molecules, and Diseases, 1998, 24, 448-461.	1.4	52
117	Evidence for the Regulation of Urokinase and Tissue Type Plasminogen Activators by the Serpin, Protein C Inhibitor, in Semen and Blood Plasma. Thrombosis and Haemostasis, 1993, 70, 0989-0994.	3.4	52
118	Formation of the Fibrin Clot: the Balance of Procoagulant and Inhibitory Factors. Clinics in Haematology, 1985, 14, 281-342.	2.3	51
119	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood, 2000, 96, 585-593.	1.4	50
120	Preclinical Safety and Pharmacokinetic Profile of 3K3A-APC, a Novel, Modified Activated Protein C for Ischemic Stroke. Current Pharmaceutical Design, 2012, 18, 4215-4222.	1.9	50
121	Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood, 2007, 109, 3733-3740.	1.4	49
122	Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays. Journal of Thrombosis and Haemostasis, 2007, 5, 102-108.	3.8	49
123	Acylcarnitines are anticoagulants that inhibit factor Xa and are reduced in venous thrombosis, based on metabolomics data. Blood, 2015, 126, 1595-1600.	1.4	49
124	Inhibition of Prothrombinase by Human Secretory Phospholipase A2 Involves Binding to Factor Xa. Journal of Biological Chemistry, 1998, 273, 23764-23772.	3.4	48
125	Activated protein C and ischemic stroke. Critical Care Medicine, 2004, 32, S247-S253.	0.9	47
126	Sphingolipids as Bioactive Regulators of Thrombin Generation. Journal of Biological Chemistry, 2004, 279, 12036-12042.	3.4	46

#	Article	IF	Citations
127	Interaction of human plasma kallikrein and its light chain with C.hivin.1 inhibitor. Biochemistry, 1983, 22, 4860-4866.	2.5	45
128	Effect of l-asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin K-dependent coagulation factors and inhibitors. Journal of Pediatrics, 1986, 108, 698-701.	1.8	45
129	The promise of protein C. Blood Cells, Molecules, and Diseases, 2006, 36, 211-216.	1.4	45
130	Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Science, 2002, 11, 2091-2101.	7.6	45
131	Tissue factor pathway inhibitor primes monocytes for antiphospholipid antibody-induced thrombosis. Blood, 2019, 134, 1119-1131.	1.4	45
132	Protein C inhibitor is expressed in tubular cells of human kidney.. Journal of Clinical Investigation, 1994, 94, 2117-2124.	8.2	45
133	Two Mutations in the Promoter Region of the Human Protein C Gene Both Cause Type I Protein C Deficiency by Disruption of Two HNF-3 Binding Sites. Journal of Biological Chemistry, 1995, 270, 24216-24221.	3.4	43
134	General and Efficient Method for the Solution- and Solid-Phase Synthesis of Vancomycin Carboxamide Derivatives. Journal of Organic Chemistry, 1995, 60, 1102-1103.	3.2	43
135	Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thrombosis and Haemostasis, 2014, 112, 883-892.	3.4	43
136	Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa. FEBS Journal, 1987, 164, 637-642.	0.2	42
137	Structural basis for type I and type II deficiencies of antithrombotic plasma protein C: Patterns revealed by three-dimensional molecular modelling of mutations of the protease domain. Proteins: Structure, Function and Bioinformatics, 1994, 18, 367-380.	2.6	42
138	Electrocatalytic Reduction of Dioxygen by Diruthenium Cofacial Diporphyrins Axially-Bound to a Gold-Supported, Self-Assembled Monolayer. Inorganic Chemistry, 1996, 35, 1751-1752.	4.0	42
139	Identification of Distinct Sequences in Human Blood Coagulation Factor Xa and Prothrombin Essential for Substrate and Cofactor Recognition in the Prothrombinase Complex. Journal of Biological Chemistry, 2003, 278, 33312-33318.	3.4	41
140	Solid-Phase Total Synthesis of Bacitracin A. Journal of Organic Chemistry, 1996, 61, 3983-3986.	3.2	40
141	Conversion of a Plant Oxidosqualene-Cycloartenol Synthase to an Oxidosqualene-Lanosterol Cyclase by Random Mutagenesisâ€. Biochemistry, 2002, 41, 8238-8244.	2.5	40
142	Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants. Journal of Thrombosis and Haemostasis, 2006, 4, 1315-1322.	3.8	40
143	NUCLEAR MAGNETIC RESONANCE STUDIES OF A RIBONUCLEASE-DINUCLEOSIDE PHOSPHONATE COMPLEX AND THEIR IMPLICATIONS FOR THE MECHANISM OF THE ENZYME. Annals of the New York Academy of Sciences, 1973, 222, 693-708.	3.8	39
144	Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Science, 1994, 3, 588-599.	7.6	39

#	Article	IF	Citations
145	Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thrombosis Research, 1978, 13, 1049-1056.	1.7	37
146	Protein S is inducible by interleukin 4 in T cells and inhibits lymphoid cell procoagulant activity. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11484-11489.	7.1	37
147	Chemical synthesis and spontaneous folding of a multidomain protein: Anticoagulant microprotein S. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14074-14078.	7.1	37
148	Cytoprotective-Selective Activated Protein C Attenuates Pseudomonas aeruginosaâ€“Induced Lung Injury in Mice. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 632-641.	2.9	37
149	Extensive Venous and Arterial Thrombosis Associated With an Inhibitor to Activated Protein C. Blood, 1999, 94, 895-901.	1.4	36
150	Effect of hyperhomocysteinemia on protein C activation and activity. Blood, 2002, 100, 2108-2112.	1.4	36
151	Plasma protein S contains zinc essential for efficient activated protein Câ€independent anticoagulant activity and binding to factor Xa, but not for efficient binding to tissue factor pathway inhibitor. FASEB Journal, 2009, 23, 2244-2253.	0.5	36
152	Organ-Specific Protection Against Lipopolysaccharide-Induced Vascular Leak Is Dependent on the Endothelial Protein C Receptor. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 769-776.	2.4	36
153	A Protein S Deficient Family with Portal Vein Thrombosis. Thrombosis and Haemostasis, 1985, 54, 724-724.	3.4	36
154	A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry, 1993, 32, 12656-12663.	2.5	35
155	Binding Site for Blood Coagulation Factor Xa Involving Residues 311â€“325 in Factor Va. Journal of Biological Chemistry, 1998, 273, 14900-14905.	3.4	35
156	Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood, 2016, 128, 1870-1878.	1.4	34
157	Complex Formation between Bovine Neurophysin-I and Oxytocin, Vasopressin, and Tripeptide Analogs of Their NH2-terminal Region. Journal of Biological Chemistry, 1973, 248, 7975-7978.	3.4	34
158	Plasma lipoproteins, hemostasis and thrombosis. Thrombosis and Haemostasis, 2001, 86, 386-94.	3.4	34
159	Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Critical Care, 2006, 10, R16.	5.8	33
160	Speciesâ€dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. Journal of Neurochemistry, 2009, 109, 116-124.	3.9	33
161	Activated protein C promotes neuroprotection: mechanisms and translation to the clinic. Thrombosis Research, 2016, 141, S62-S64.	1.7	33
162	Detection and Quantitation of Cleaved and Uncleaved High Molecular Weight Kininogen in Plasma by Ligand Blotting with Radiolabeled Plasma Prekallikrein or Factor XI. Thrombosis and Haemostasis, 1988, 59, 151-161.	3.4	33

#	Article	IF	Citations
163	Surface-dependent activation of human factor XII (Hageman factor) by Kallikrein and its light chain. FEBS Journal, 1985, 151, 531-538.	0.2	32
164	C-terminal Residues 621â€“635 of Protein S Are Essential for Binding to Factor Va. Journal of Biological Chemistry, 1999, 274, 36187-36192.	3.4	32
165	Brain-Specific Protein C Activation During Carotid Artery Occlusion in Humans. Stroke, 1999, 30, 542-545.	2.0	32
166	2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2143-2151.	2.4	32
167	Apolipoprotein E Receptor 2 Mediates Activated Protein Câ€“Induced Endothelial Akt Activation and Endothelial Barrier Stabilization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 518-524.	2.4	31
168	Enhanced specificity of immunoblotting using radiolabeled antigen overlay: Studies of blood coagulation factor XII and prekallikrein in plasma. Analytical Biochemistry, 1986, 156, 118-125.	2.4	30
169	Impaired Anticoagulant Response to Infusion of Thrombin in Atherosclerotic Monkeys Associated With Acquired Defects in the Protein C System. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1744-1750.	2.4	30
170	Conformational changes in activated protein C caused by binding of the first epidermal growth factor-like module of protein S. Biochemical Journal, 2000, 349, 757-764.	3.7	30
171	Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Alaâ€activated protein C mediated by factor Va. Protein Science, 1997, 6, 132-140.	7.6	29
172	Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant. Journal of Thrombosis and Haemostasis, 2014, 12, 363-372.	3.8	29
173	Hormonal interactions at the molecular level: A high resolution proton magnetic resonance study of bovine neurophysins and their interactions with oxytocin. FEBS Letters, 1972, 25, 282-286.	2.8	28
174	Assignment of an exchangeable low-field nitrogen-hydrogen proton resonance of ribonuclease A to the active-site hisitidine-119. Biochemistry, 1973, 12, 2096-2099.	2.5	28
175	Interactions and inhibition of blood coagulation factor Va involving residues 311â€“325 of activated protein C. Protein Science, 1993, 2, 1482-1489.	7.6	28
176	Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice. Blood, 2015, 126, 2415-2423.	1.4	28
177	Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Molecular Neurodegeneration, 2011, 6, 13.	10.8	27
178	Exacerbated venous thromboembolism in mice carrying a protein S K196E mutation. Blood, 2015, 126, 2247-2253.	1.4	27
179	Design of a DNA-Programmed Plasminogen Activator. Journal of the American Chemical Society, 2018, 140, 15516-15524.	13.7	27
180	Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. Journal of Thrombosis and Haemostasis, 2005, 3, 935-938.	3.8	26

#	Article	IF	Citations
181	Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. Thrombosis and Haemostasis, 2008, 99, 453-455.	3.4	26
182	Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently. Circulation Research, 2021, 128, 513-529.	4.5	26
183	Complexes of activated protein C with Î±1-antitrypsin in normal pregnancy and in severe preeclampsia. American Journal of Obstetrics and Gynecology, 1991, 164, 1310-1316.	1.3	25
184	Generation of activated protein C during thrombolysis. Lancet, The, 1993, 342, 1275-1276.	13.7	25
185	Prothrombin Residues 473â€“487 Contribute to Factor Va Binding in the Prothrombinase Complex. Journal of Biological Chemistry, 2004, 279, 49019-49025.	3.4	25
186	Characterization of a Factor Xa Binding Site on Factor Va near the Arg-506 Activated Protein C Cleavage Site. Journal of Biological Chemistry, 2007, 282, 21848-21855.	3.4	25
187	Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Research, 2013, 1507, 97-104.	2.2	25
188	Protein S, an Antithrombotic Factor, Is Synthesized and Released by Neural Tumor Cells. Journal of Neurochemistry, 1993, 61, 344-347.	3.9	24
189	Cardiopulmonary bypass and activation of antithrombotic plasma protein C. Journal of Thoracic and Cardiovascular Surgery, 1999, 118, 422-431.	0.8	24
190	The TLR4-PAR1 Axis Regulates Bone Marrow Mesenchymal Stromal Cell Survival and Therapeutic Capacity in Experimental Bacterial Pneumonia. Stem Cells, 2018, 36, 796-806.	3.2	24
191	Dermatan Sulfate and LMW Heparin Enhance the Anticoagulant Action of Activated Protein C. Thrombosis and Haemostasis, 1999, 82, 1462-1468.	3.4	24
192	Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.. Journal of Clinical Investigation, 1997, 99, 2655-2663.	8.2	24
193	Coagulation Pathways in Atherothrombosis. Trends in Cardiovascular Medicine, 2002, 12, 317-324.	4.9	23
194	Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. American Journal of Hematology, 1978, 4, 401-407.	4.1	22
195	Cardiolipin Enhances Protein C Pathway Anticoagulant Activity. Blood Cells, Molecules, and Diseases, 2000, 26, 115-123.	1.4	22
196	Anticoagulant Responses to Thrombin Are Enhanced During Regression of Atherosclerosis in Monkeys. Circulation, 2002, 106, 842-846.	1.6	22
197	Factor V Is an Anticoagulant Cofactor for Activated Protein C during Inactivation of Factor Va. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2010, 37, 17-23.	0.3	22
198	COVIDâ€19 hypothesis: Activated protein C for therapy of virusâ€induced pathologic thromboinflammation. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 506-509.	2.3	22

#	Article	IF	Citations
199	The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood, 2000, 96, 585-593.	1.4	22
200	Interactions of Bovine Neurophysin II with Oxytocin and [8-Lysine] Vasopressin. Journal of Biological Chemistry, 1974, 249, 6895-6900.	3.4	22
201	Rabbit blood coagulation factor XI. Purification and properties. Thrombosis Research, 1979, 15, 475-486.	1.7	21
202	Studies on human protein C inhibitor in normal and factor V/VIII deficient plasmas. Thrombosis Research, 1984, 36, 197-203.	1.7	21
203	The Carbohydrate Moiety of Factor V Modulates Inactivation by Activated Protein C. Blood, 1997, 89, 4348-4354.	1.4	21
204	Glucosylceramide, a Neutral Glycosphingolipid Anticoagulant Cofactor, Enhances the Interaction of Human- and Bovine-activated Protein C with Negatively Charged Phospholipid Vesicles. Journal of Biological Chemistry, 2003, 278, 14614-14621.	3.4	21
205	Human plasma phospholipid transfer protein specific activity is correlated with HDL size: Implications for lipoprotein physiology. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 206-211.	2.4	21
206	Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa. Thrombosis and Haemostasis, 2016, 115, 551-561.	3.4	21
207	FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1275-1288.	2.4	21
208	Analysis of Protein S C4b-Binding Protein Interactions by Homology Modeling and Inhibitory Antibodies. Biochemistry, 1994, 33, 11073-11078.	2.5	20
209	Design, synthesis and in vitro evaluation of pyridinium ion based cyclase inhibitors and antifungal agents. Bioorganic and Medicinal Chemistry, 1996, 4, 97-103.	3.0	20
210	Activated Protein C Reduces Graft Neutrophil Activation in Clinical Renal Transplantation. American Journal of Transplantation, 2005, 5, 2204-2212.	4.7	20
211	Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. Frontiers in Cellular Neuroscience, 2015, 9, 344.	3.7	20
212	Interaction of Plasma Kallikrein with Protein C Inhibitor in Purified Mixtures and in Plasma. Thrombosis and Haemostasis, 1991, 65, 046-051.	3.4	20
213	STUDIES OF BOVINE NEUROPHYSIN-NEUROHYPOPHYSEAL HORMONE INTERACTIONS. Annals of the New York Academy of Sciences, 1975, 248, 463-479.	3.8	19
214	Carbon-13 nuclear magnetic resonance studies on (85% 13 C-enriched Gly9) oxytocin. FEBS Letters, 1975, 50, 168-171.	2.8	19
215	13-C nuclear magnetic resonance studies of the binding of selectively 13C -enriched oxytocins to the neurohypophyseal protein, bovine neurophysin II. Biochemistry, 1977, 16, 4194-4198.	2.5	19
216	The effect of tryptase from human mast cells on human prekallikrein. Biochemical and Biophysical Research Communications, 1985, 129, 76-81.	2.1	19

#	Article	IF	Citations
217	Involvement of Amino Acid Residues 423â€“429 of Human Protein S in Binding to C4b-Binding Protein. Blood Cells, Molecules, and Diseases, 1998, 24, 101-112.	1.4	19
218	Neutral Glycosphingolipid-dependent Inactivation of Coagulation Factor Va by Activated Protein C and Protein S. Journal of Biological Chemistry, 2002, 277, 8861-8865.	3.4	19
219	Protein C Pathway Impairment in Nonsymptomatic Cigarette Smokers. Blood Cells, Molecules, and Diseases, 2002, 29, 73-82.	1.4	19
220	Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins: Structure, Function and Bioinformatics, 2004, 54, 433-441.	2.6	19
221	Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica, 2009, 94, 1721-1731.	3.5	19
222	Activated Protein C Attenuates Experimental Autoimmune Encephalomyelitis Progression by Enhancing Vascular Integrity and Suppressing Microglial Activation. Frontiers in Neuroscience, 2020, 14, 333.	2.8	19
223	Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module. Biopolymers, 1998, 46, 53-63.	2.4	18
224	Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4108-4114.	2.2	18
225	Safety, Stability and Pharmacokinetic Properties of superFactor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding. Pharmaceutical Research, 2016, 33, 1517-1526.	3.5	18
226	SCH79797 improves outcomes in experimental bacterial pneumonia by boosting neutrophil killing and direct antibiotic activity. Journal of Antimicrobial Chemotherapy, 2018, 73, 1586-1594.	3.0	18
227	Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect. Blood, 2021, 137, 3428-3442.	1.4	18
228	Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.. Journal of Clinical Investigation, 1986, 78, 170-176.	8.2	18
229	Mechanisms for Mortality Reduction by Activated Protein C in Severe Sepsis.. Blood, 2006, 108, 1-1.	1.4	18
230	Activated Protein C-Dependent and â€“Independent Anticoagulant Activities of Protein S Have Different Structural Requirements. Blood Cells, Molecules, and Diseases, 2002, 29, 190-199.	1.4	17
231	An Engineered Factor Va Prevents Bleeding Induced by Anticoagulant wt Activated Protein C. PLoS ONE, 2014, 9, e104304.	2.5	17
232	Quantitative Immunoblotting of Plasma and Platelet Protein S. Thrombosis and Haemostasis, 1986, 56, 382-386.	3.4	17
233	Platelet protein S limits venous but not arterial thrombosis propensity by controlling coagulation in the thrombus. Blood, 2020, 135, 1969-1982.	1.4	17
234	Alternative PCR method for diagnosis of mutation causing activated protein C resistant Gln506-factor V. Thrombosis Research, 1995, 80, 441-443.	1.7	16

#	Article	IF	Citations
235	Activated protein C and inflammation in human myocardium after heart surgery. American Journal of Hematology, 2001, 67, 210-212.	4.1	16
236	A novel ELISA for mouse activated protein C in plasma. Journal of Immunological Methods, 2006, 314, 174-181.	1.4	16
237	Elevated plasma fibronectin levels associated with venous thromboembolism. Thrombosis and Haemostasis, 2008, 100, 224-228.	3.4	16
238	Comparative modeling of the three CP modules of the ÃŸ-chain of C4BP and evaluation of potential sites of interaction with protein S. Protein Engineering, Design and Selection, 1995, 8, 1253-1258.	2.1	15
239	Resistance to Activated Protein C: A Common Inherited Cause of Venous Thrombosis. Annals of Vascular Surgery, 1996, 10, 174-177.	0.9	15
240	Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery, 2007, 133, 44-51.	0.8	15
241	The Thrombin-sensitive Region of Protein S Mediates Phospholipid-dependent Interaction with Factor Xa*. Journal of Biological Chemistry, 2008, 283, 33046-33052.	3.4	15
242	Elevated serum amyloid A is associated with venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 358-359.	3.4	15
243	Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C. Neuropharmacology, 2018, 134, 293-301.	4.1	15
244	PLATELET-COAGULANT PROTEIN INTERACTIONS IN CONTACT ACTIVATION*. Annals of the New York Academy of Sciences, 1981, 370, 241-252.	3.8	14
245	ALTERNATIVE PATHWAYS OF THROMBOPLASTIN-DEPENDENT ACTIVATION OF HUMAN FACTOR X IN PLASMA*. Annals of the New York Academy of Sciences, 1981, 370, 325-335.	3.8	14
246	Factor Va Increases the Affinity of Factor Xa for Prothrombin. Chemistry and Biology, 2002, 9, 485-494.	6.0	14
247	Activation of protein C during reperfusion in clinical liver transplantation. Transplantation, 2003, 75, 467-472.	1.0	14
248	Minor plasma lipids modulate clotting factor activities and may affect thrombosis risk. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 93-102.	2.3	14
249	Regulation of immune cell signaling by activated protein C. Journal of Leukocyte Biology, 2018, 103, 1197-1203.	3.3	14
250	Immunoblotting Studies of Coagulation Factor XII, Plasma Prekallikrein, and High Molecular Weight Kininogen. Seminars in Thrombosis and Hemostasis, 1987, 13, 106-114.	2.7	13
251	Competition of activated protein C and urokinase for a heparinâ€dependent inhibitor 1. FASEB Journal, 1988, 2, 2263-2267.	0.5	13
252	Two Multiplex PCR-Based DNA Assays for the Thrombosis Risk Factors Prothrombin G20210A and Coagulation Factor V G1691A Polymorphisms. Thrombosis Research, 1999, 93, 265-269.	1.7	13

#	Article	IF	Citations
253	Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. Journal of Atherosclerosis and Thrombosis, 2016, 23, 1159-1167.	2.0	13
254	Î±2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:Î±2M Levels Are Associated with Venous Thromboembolism. Thrombosis and Haemostasis, 2018, 47, 630-638.	3.4	13
255	Novel exomic rare variants associated with venous thrombosis. British Journal of Haematology, 2020, 190, 783-786.	2.5	13
256	Oral anticoagulation reduces activated protein C less than protein C and other vitamin Kâ€“dependent clotting factors. Blood, 2002, 100, 4232-4233.	1.4	12
257	Factor Va Residues 311â€“325 Represent an Activated Protein C Binding Region. Journal of Biological Chemistry, 2007, 282, 28353-28361.	3.4	12
258	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. Blood, 2019, 134, 776-781.	1.4	12
259	Plasma cholesteryl ester transfer protein and blood coagulability. Thrombosis and Haemostasis, 2007, 98, 1160-1164.	3.4	12
260	Protection of ischemic white matter and oligodendrocytes in mice by 3K3A-activated protein C. Journal of Experimental Medicine, 2022, 219, .	8.5	12
261	Upregulation of the Antithrombotic Protein C Pathway at Birth. Pediatric Hematology and Oncology, 1998, 15, 489-499.	0.8	11
262	Human Thrombomodulin Knock-In Mice Reveal Differential Effects of Human Thrombomodulin on Thrombosis and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2509-2517.	2.4	11
263	Incorporation of Disulfide Containing Protein Modules into Multivalent Antigenic Conjugates: Generation of Antibodies against the Thrombin-Sensitive Region of Murine Protein S. Journal of the American Chemical Society, 2012, 134, 19318-19321.	13.7	11
264	Re-Evaluation of the Anticoagulant Properties of High-Density Lipoproteinâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 570-572.	2.4	11
265	Cardiac and Skeletal Muscle Myosin Exert Procoagulant Effects. Shock, 2019, 52, 554-555.	2.1	11
266	PAR1 regulation of CXCL1 expression and neutrophil recruitment to the lung in mice infected with influenza A virus. Journal of Thrombosis and Haemostasis, 2021, 19, 1103-1111.	3.8	11
267	Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation. Frontiers in Neurology, 2021, 12, 593582.	2.4	11
268	Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. Thrombosis and Haemostasis, 2009, 101, 55-61.	3.4	11
269	Activated Protein C Strengthens Cardiac Tolerance to Ischemic Insults in Aging. Circulation Research, 2022, 130, 252-272.	4.5	11
270	Rabbit blood coagulation factor XI. Mechanism of activation by rabbit Hageman factor (factor XII). Thrombosis Research, 1979, 15, 487-495.	1.7	10

#	Article	IF	Citations
271	Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. British Journal of Haematology, 2006, 132, 197-203.	2.5	10
272	Molecular interaction site on procoagulant myosin for factor Xaâ€“dependent prothrombin activation. Journal of Biological Chemistry, 2019, 294, 15176-15181.	3.4	10
273	Activated protein C and PAR1â€derived and PAR3â€derived peptides are antiâ€inflammatory by suppressing macrophage NLRP3 inflammasomes. Journal of Thrombosis and Haemostasis, 2021, 19, 269-280.	3.8	10
274	Sex-dependent effects of genetic upregulation of activated protein C on delayed effects of acute radiation exposure in the mouse heart, small intestine, and skin. PLoS ONE, 2021, 16, e0252142.	2.5	10
275	Functional Assays for Protein C Activity and Protein C Inhibitor Activity in Plasma. Thrombosis and Haemostasis, 1989, 61, 086-092.	3.4	10
276	Activated protein C correlates inversely with thrombin levels in resting healthy individuals. , 1997, 56, 29-31.		9
277	Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II. British Journal of Haematology, 2002, 117, 676-684.	2.5	9
278	Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells, Molecules, and Diseases, 2013, 51, 104-108.	1.4	9
279	Activated Protein C Resistance: What Have We Learned Now That the Dust Has Settled?. Annals of Medicine, 1997, 29, 469-472.	3.8	8
280	Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation. Critical Care Medicine, 2006, 34, 426-432.	0.9	8
281	Cholesteryl ester transfer protein genotypes associated with venous thrombosis and dyslipoproteinemia in males. Journal of Thrombosis and Haemostasis, 2006, 4, 2080-2082.	3.8	8
282	Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids. British Journal of Haematology, 2014, 165, 409-412.	2.5	8
283	Physiological cerebrovascular remodeling in response to chronic mild hypoxia: A role for activated protein C. Experimental Neurology, 2016, 283, 396-403.	4.1	8
284	A Two-Allele Polymorphism in Protein C Inhibitor with Varying Frequencies in Different Ethnic Populations. Thrombosis and Haemostasis, 1996, 75, 062-069.	3.4	8
285	3K3A-Activated Protein C Protects the Blood-Brain Barrier and Neurons From Accelerated Ischemic Injury Caused by Pericyte Deficiency in Mice. Frontiers in Neuroscience, 2022, 16, 841916.	2.8	8
286	Sulfatide bilayers as a surface for contact activation in human plasma. Biochemical and Biophysical Research Communications, 1987, 149, 1002-1007.	2.1	7
287	Enantiotracin. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2239-2240.	2.2	7
288	Association of Apo(a)isoform size with dyslipoproteinemia in male Venous Thrombosis patients. Clinica Chimica Acta, 2010, 411, 1279-1283.	1.1	7

#	Article	IF	Citations
289	Infrared fluorescence for vascular barrier breach in vivo â€“ A novel method for quantitation of albumin efflux. Thrombosis and Haemostasis, 2012, 108, 981-991.	3.4	7
290	Influence of the 3K3Aâ€activated protein C variant on the plasma clot lysis activity of tâ€PA and of tâ€PA on the variant's anticoagulant activity. Journal of Thrombosis and Haemostasis, 2013, 11, 2059-2062.	3.8	7
291	Low level of the plasma sphingolipid, glucosylceramide, is associated with thrombotic diseases. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 33-40.	2.3	7
292	Cardiac Myosin Promotes Thrombin Generation and Coagulation In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 901-913.	2.4	7
293	Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin. Journal of Thrombosis and Haemostasis, 2021, 19, 7-19.	3.8	7
294	Insight in Protein S Deficiency From Mouse Models. Blood, 2011, 118, 529-529.	1.4	7
295	Drugâ€“Biomolecule Interactions: Proton Magnetic Resonance Studies of Complex Formation between Bovine Neurophysins and Oxytocin at Molecular Level. Journal of Pharmaceutical Sciences, 1975, 64, 507-511.	3.3	6
296	Evolution of Sterol and Triterpene Cyclases. ACS Symposium Series, 1994, , 44-54.	0.5	6
297	Plasma protein S residues 37â€“50 mediate its binding to factor Va and inhibition of blood coagulation. Thrombosis and Haemostasis, 2013, 110, 275-282.	3.4	6
298	Inhibition of thrombin generation in human plasma by phospholipid transfer protein. Thrombosis Journal, 2015, 13, 24.	2.1	6
299	Protective Effect of Activated Protein C in Murine Endotoxemia: Mechanism of Action.. Blood, 2005, 106, 26-26.	1.4	6
300	Skeletal muscle myosin promotes coagulation by binding factor XI via its A3 domain and enhancing thrombin-induced factor XI activation. Journal of Biological Chemistry, 2022, 298, 101567.	3.4	6
301	Correlations among the DNA binding/cleaving specificities of small molecules revealed by double-strand affinity cleaving. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 73-76.	2.2	5
302	Activated Protein C in the Cardioplegic Solution on a Porcine Model of Coronary Ischemia-Reperfusion has Deleterious Hemodynamic Effects. Cardiovascular Drugs and Therapy, 2006, 20, 113-121.	2.6	5
303	Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Blood Cells, Molecules, and Diseases, 2013, 50, 252-258.	1.4	5
304	Activated protein C anticoagulant activity is enhanced by skeletal muscle myosin. Haematologica, 2020, 105, e424-e427.	3.5	5
305	An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms. Blood Advances, 2020, 4, 3716-3727.	5.2	5
306	Activated Protein C (APC) and 3K3A-APC-Induced Regression of Choroidal Neovascularization (CNV) Is Accompanied by Vascular Endothelial Growth Factor (VEGF) Reduction. Biomolecules, 2021, 11, 358.	4.0	5

#	Article	IF	Citations
307	Addendum: American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genetics in Medicine, 2021, 23, 2463.	2.4	5
308	Possible Structural Implications of 20 Mutations in the Protein C Protease Domain. Thrombosis and Haemostasis, 1994, 72, 869-873.	3.4	5
309	Whole Blood Thromboelastogram Assays Demonstrate Prolonged Factor VIIIa Potency for Recombinant Disulfide Bond-Stabilized Factor VIII Variants.. Blood, 2004, 104, 2976-2976.	1.4	5
310	Plasma cholesteryl ester transfer protein and blood coagulability. Thrombosis and Haemostasis, 2007, 98, 1160-4.	3.4	5
311	Chapter 5A Initiation mechanisms: The contact activation system in plasma. New Comprehensive Biochemistry, 1986, , 103-128.	0.1	4
312	High molecular weight kininogen receptor. Methods in Enzymology, 1992, 215, 369-382.	1.0	4
313	Exonic polymorphisms in the protein C gene: interethnic comparison between Caucasians and Asians. Human Genetics, 1994, 94, 177-8.	3.8	4
314	Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex. PLoS ONE, 2015, 10, e0135025.	2.5	4
315	Neuroprotection and vasculoprotection using genetically targeted protease-ligands. Brain Research, 2019, 1715, 13-20.	2.2	4
316	Câ€terminal residues of activated protein C light chain contribute to its anticoagulant and cytoprotective activities. Journal of Thrombosis and Haemostasis, 2020, 18, 1027-1038.	3.8	4
317	Plasma skeletal muscle myosin phenotypes identified by immunoblotting are associated with pulmonary embolism occurrence in young adults. Thrombosis Research, 2020, 189, 88-92.	1.7	4
318	Risk of Recurrent Venous Thromboembolism Reduced by High Density Lipoproteins.. Blood, 2006, 108, 271-271.	1.4	4
319	Anti-Inflammatory and Anti-Apoptotic Activities of Activated Protein C Are Independent of Anticoagulant Activity.. Blood, 2006, 108, 65-65.	1.4	4
320	Factor V Inhibits PAR2-Mediated Lethal Inflammation. Blood, 2012, 120, 3360-3360.	1.4	4
321	Reversal of Novel Oral Anticoagulant (NOAC)-Induced Bleeding in Mice By Engineered superfactor Va. Blood, 2014, 124, 695-695.	1.4	4
322	Novel Infrared Fluorescence Methodology Defines An Essential Role for Endothelial Protein C Receptor (EPCR) for Protection Against Vascular Leakage In Inflammation. Blood, 2010, 116, 653-653.	1.4	4
323	Elevated plasma fibronectin levels associated with venous thromboembolism. Thrombosis and Haemostasis, 2008, 100, 224-8.	3.4	4
324	An optimized method for the isolation of urinary extracellular vesicles for molecular phenotyping: detection of biomarkers for radiation exposure. Journal of Translational Medicine, 2022, 20, 199.	4.4	4

#	Article	IF	Citations
325	Application of nuclear magnetic resonance spectroscopy to proteins. Biochimie, 1975, 57, 453-460.	2.6	3
326	Effects of subperineurial injections of very-long-chain and medium-chain fatty acids into rat sciatic nerve. Neurochemical Pathology, 1986, 5, 71-83.	1.1	3
327	Circulating Activated Protein C inSubjects with Heterozygous Gln506-Factor V. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1998, 28, 31-36.	0.3	3
328	Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. Thrombosis Research, 2012, 129, 502-507.	1.7	3
329	Removal of Coagulation Factors by the GamunexÂ®-C Purification Process. Journal of Allergy and Clinical Immunology, 2013, 131, AB10.	2.9	3
330	Activated protein C light chain provides an extended binding surface for its anticoagulant cofactor, protein S. Blood Advances, 2017, 1, 1423-1426.	5.2	3
331	Serum amyloid A4 is a procoagulant apolipoprotein that it is elevated in venous thrombosis patients. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 217-223.	2.3	3
332	Fullâ€length plasma skeletal muscle myosin isoform deficiency is associated with coagulopathy in acutely injured patients. Journal of Thrombosis and Haemostasis, 2022, 20, 1385-1389.	3.8	3
333	EPCR-PAR1 biased signaling regulates perfusion recovery and neovascularization in peripheral ischemia. JCI Insight, 2022, 7, .	5.0	3
334	Anticoagulant Dysfunction of Human Arg352Trp-Activated Protein C Caused by Defective Factor Va Inactivation. Thrombosis and Haemostasis, 2001, 85, 274-279.	3.4	2
335	Cholesterol enhances phospholipid-dependent activated protein C anticoagulant activity. Journal of Thrombosis and Haemostasis, 2005, 3, 340-345.	3.8	2
336	Is adiponectin implicated in venous thromboembolism?. Journal of Thrombosis and Haemostasis, 2006, 4, 1151-1152.	3.8	2
337	Activation-resistant homozygous protein C R229W mutation causing familial perinatal intracranial hemorrhage and delayed onset of thrombosis. Thrombosis Research, 2016, 143, 17-21.	1.7	2
338	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. Blood, 2021, 137, 1839-1842.	1.4	2
339	Synergistic Effect in Bleed Reduction By superfva and Recombinant Human FVIIa in Vivo Suggests a Novel Bypassing Strategy for Hemophilia Patients with Inhibitors. Blood, 2014, 124, 692-692.	1.4	2
340	Exome Genotyping Links Venous Thrombosis Risk with the Skeletal Muscle Myosin Gene Cluster and Leads to Discovery of New Family of Procoagulant Factors. Blood, 2015, 126, 763-763.	1.4	2
341	In Vivo Anti-Thrombotic Potency of Engineered Activated Protein C Variants.. Blood, 2007, 110, 2704-2704.	1.4	2
342	Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution. Journal of Thrombosis and Haemostasis, 2014, 12, 90-92.	3.8	1

#	Article	IF	Citations
343	3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase. Stroke, 2020, 51, 2236-2239.	2.0	1
344	Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombinâ€dependent anticoagulant activity. Journal of Thrombosis and Haemostasis, 2021, 19, 470-477.	3.8	1
345	Molecular Interaction Site on Procoagulant Skeletal Muscle Myosin for Factor Xa-Dependent Prothrombin Activation. Blood, 2019, 134, 3622-3622.	1.4	1
346	Plasma High Density Lipoprotein and Anticoagulant Response to Activated Protein C (APC) and Protein S. Blood, 2011, 118, 2249-2249.	1.4	1
347	Non-Canonical Cleavage of Protease Activated Receptor 1 (PAR1) by Activated Protein C Provides Novel Insights Into the Repertoire of Cytoprotective and Proinflammatory PAR1 Signaling. Blood, 2011, 118, 534-534.	1.4	1
348	Efficient Barrier Protective Signaling by Activated Protein C Is Mechanistically Linked to Protein C Activation on Endothelial Cells.. Blood, 2005, 106, 28-28.	1.4	1
349	Factor V as Anticoagulant Cofactor for Activated Protein C in Factor Va Inactivation. Blood, 2008, 112, 3075-3075.	1.4	1
350	Plasma Serum Amyloid A Levels Are Increased In Venous Thrombosis Patients and Are Correlated with Blood Coagulability. Blood, 2010, 116, 155-155.	1.4	1
351	Warfarin Untargeted Metabolomics Study Identifies Novel Procoagulant Ethanolamide Lipids. Blood, 2011, 118, 1200-1200.	1.4	1
352	Superior in Vivo Hemostatic Properties of an Engineered Factor Va Variant for Hemophilia Mice. Blood, 2012, 120, 17-17.	1.4	1
353	Reduction Of Histone H1 Cytotoxicity By Activated Protein C and Its Exosite Variants. Blood, 2013, 122, 2334-2334.	1.4	1
354	The Function of the Heavy and Light Chain of Human Plasma Kallikrein in the Activation of Factor XII. Advances in Experimental Medicine and Biology, 1986, 198 Pt B, 27-34.	1.6	1
355	Blocking Protein S Improves Hemostasis in Hemophilia a and B. Blood, 2016, 128, 79-79.	1.4	1
356	Novel R41Q- and R46Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for In Vivo Protective Mechanisms of Action for Activated Protein C (APC) in Sepsis and Stroke. Blood, 2016, 128, 13-13.	1.4	1
357	Sars-Cov-2 Infection Promotes Endothelial Dysfunction and Thrombosis in a Mouse Model of COVID-19. Blood, 2021, 138, 999-999.	1.4	1
358	MECHANISMS FOR THE CONVERSION OF BLOOD COAGULATION PROENZYMES TO ENZYMES. , 1983, , 201-224.		0
359	Anticoagulant response to activated protein c: Method validation and assay comparison. Journal of Clinical Laboratory Analysis, 1995, 9, 418-423.	2.1	0
360	Causes of Thrombophilia Yet to Be Discovered: A Personal View. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2000, 30, 26-33.	0.3	0

#	Article	IF	Citations
361	Factor Xa Binding Sites on Factor Va in the Prothrombinase Complex.. Blood, 2004, 104, 1713-1713.	1.4	0
362	Targeted Replacement of the Murine Thrombomodulin Gene with Human Thrombomodulin Coding Sequence Results in Decreased Protein C Activation and Enhanced Thrombotic Response to Photochemical Injury.. Blood, 2004, 104, 2980-2980.	1.4	0
363	Sustained Pharmacological Activation of Protein C (PC) in Baboons.. Blood, 2004, 104, 3499-3499.	1.4	0
364	Activated Protein C Light Chain Mutations Distinguish Exosite Residue Requirements for Anticoagulant Versus Cytoprotective Activities.. Blood, 2005, 106, 29-29.	1.4	0
365	Platelet Factor 4 (PF4) Modulation of Endothelial Protein C Receptor and Thrombomodulin Enhancements of Protein C Activation and TAFI Activation by Thrombin.. Blood, 2006, 108, 1791-1791.	1.4	0
366	Preservation of Beneficial TAFI Functions by an Activated Protein C Variant with Normal Cytoprotective Functions but Minimal Anticoagulant Activity.. Blood, 2007, 110, 268-268.	1.4	0
367	Activation of the PI3K-Akt Pathway by Activated Protein C Occurs Via a Novel Receptor, Apolipoprotein E Receptor 2 (ApoER2). Blood, 2008, 112, 695-695.	1.4	0
368	Lyso-Sulfatide Binds Factor Xa and Potently Inhibits Thrombin Generation.. Blood, 2010, 116, 1130-1130.	1.4	0
369	Activated Protein C Cellular Pathways Regulating Thrombosis. Blood, 2011, 118, SCI-44-SCI-44.	1.4	0
370	In Vitro and in Vivo Neutralization of Murine Activated Protein C. Blood, 2012, 120, 3364-3364.	1.4	0
371	Protection Against Vascular Leakage in Vivo by a Peptide Mimetic of the Novel Tethered Ligand Generated by Non-Canonical Cleavage of Protease Activated Receptor 1 by Activated Protein C. Blood, 2012, 120, 497-497.	1.4	0
372	Activated Protein C Cytoprotective Signaling in Endothelial Cells Involves apoER2 and Disabled-1. Blood, 2012, 120, 1102-1102.	1.4	0
373	An Engineered Factor Fva Prevents Bleeding Induced By Anticoagulant Wild Type Activated Protein C. Blood, 2013, 122, 203-203.	1.4	0
374	Activation-Resistant Homozygous Protein C R229W Mutation Causing Familial Perinatal Intracranial Hemorrhage. Blood, 2013, 122, 3587-3587.	1.4	0
375	Overview on Blood Coagulation Proteins. , 1984, , 39-55.		0
376	Novel R41Q-PAR1-Modified Mice Enable Proof-of-Concept Studies for in Vivo Mechanisms of Action for Thrombin (IIa) and Activated Protein C (APC). Blood, 2014, 124, 99-99.	1.4	0
377	Acylcarnitines Are Novel Anticoagulant Lipids That Target Factor Xa and That Are Reduced in Plasma of Venous Thrombosis Patients Based on Untargeted and Targeted Metabolomics. Blood, 2014, 124, 2797-2797.	1.4	0
378	Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C. Blood, 2015, 126, 216-216.	1.4	0

#	Article	IF	Citations
379	Role of Protein S and Gas6 in the Development of Purpura Fulminans. Blood, 2015, 126, 1042-1042.	1.4	0
380	Plasma Constitutive Serum Amyloid A4 Is Procoagulant and Is Elevated in Venous Thrombosis Patients. Blood, 2015, 126, 3486-3486.	1.4	0
381	Activated Protein C (APC) Therapy Ameliorates Chronic Graft Versus Host Disease By Cell Signaling Mechanisms That Require Cleavage at Arg46 in PAR1 on T Cells. Blood, 2016, 128, 808-808.	1.4	0
382	Factor VIIa Induces Biased Cytoprotective Signaling through the Cleavage of Protease Activated Receptor 1 at Canonical Arg41 Site. Blood, 2019, 134, 481-481.	1.4	0
383	Cardiac Myosin Acts Is a Potent Procoagulant in Vitro and In Vivo. Blood, 2019, 134, 3632-3632.	1.4	0
384	Skeletal Muscle Myosin Is Procoagulant By Binding Factor XI Via Its A3 Domain and Enhancing Factor XI Activation By Thrombin. Blood, 2021, 138, 441-441.	1.4	0